NOW-HEALTH-INTERNATIONAL
Award-winning International Private Medical Insurance (IPMI) provider Now Health International is celebrating its latest customer service success, having won another prestigious award, Customer Service Initiative of the Year, recognising its leadership in this area.
In addition to its TrustPilot score reflecting how the company’s members feel about its products and service, Now Health International also uses an internal survey program to proactively address customer issues and make life even easier for its members.
However, the company believes a vital point of difference in the marketplace comes from its empathetic and efficient approach to dealing with members’ claims. Now Health International reports that it processes and pays 99% of members’ claims within five working days, which is one of the core components of the company’s Service Promise. Additionally, the company approves 95% of all claims upon submission, without needing to gather more information from members.
But while many insurers are fully automating these processes – and seeing mixed results – Now Health International relies on human expertise and personal qualities like empathy and compassion to enhance its claims processes.
Discussing the company’s claims philosophy, Michel Faucher, Managing Director, Now Health International, said: “We believe in the value of the human touch and are committed to providing personalised care and support to all our members, especially when they’re making claims, which will often come after going through a particularly stressful period of illness or injury.
“Our approach is to look for all the right reasons to pay a claim. While we use automation to assist with fast claims processing and payment, we never outright reject a claim purely on a machine’s decision. Where our tools recommend further investigation, our team of claims specialists then get involved, more often than not leading to members’ claims being processed.”
Dr Bilal Shirazi, Chief Medical Officer, Now Health International, added: “Technology undoubtedly has a role to play in what we do, but there is no substitute for the empathy, care and compassion that humans can provide during a one-on-one interaction.
“I’m incredibly proud of the difference we’ve made to our members’ lives by using technology to make our processes more efficient while freeing up time for dedicated human involvement where necessary.”
Faucher concluded: “We’re incredibly passionate about using technology to disrupt the insurance industry and be innovators, but the human touch will always come first. I invite anyone seeking IPMI worldwide to come and experience the benefits of our approach first-hand, while also taking advantage of some fantastic deals we’re currently offering.”
About Now Health International
Now Health International (NHI) is one of the fastest growing providers of International Private Medical Insurance (IPMI) solutions for Global Expatriates, High-Net-Worth individuals and Companies. NHI has offices in the UK, Malta, Spain, UAE, China, Hong Kong, Singapore and Indonesia.
For more information, visit https://www.now-health.com/.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809033032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson’s Disease at the 28th Annual ASGCT Meeting in New Orleans13.5.2025 08:00:00 CEST | Press release
TreeFrog Therapeutics is the first company to present publicly a clinical-ready delivery strategy for 3D format microtissues in cell therapy.After four years in development, the validated device and delivery strategy overcomes challenges of 3D formats and uses existing stereotactic components to support adoption through ease of delivery education. TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It is a progressive disease characterized by the loss of dopaminergic neurons with a mix of motor symptoms (bradykinesia, rigidity, resting tremor) and non-motor symptoms (cognitive deficits, mood disorders, fatigue). Current treatments provide symptomatic re
Ohana Development Launches ‘Jacob & Co. Beachfront Living by Ohana,’ A Masterpiece of Beachfront Elegance in the UAE13.5.2025 08:00:00 CEST | Press release
Valued at USD 1.3 billion, the project offers world-class amenities, including a signature Jacob & Co. ceiling art timepiece, the largest of its kind globally. Ohana Development, the leading real estate developer renowned for its luxury properties, has launched ‘Jacob & Co. Beachfront Living by Ohana’ in partnership with luxury timepiece and jewellery house Jacob & Co. The project was revealed at Emirates Palace Mandarin Oriental, Abu Dhabi. Located in Al Jurf between Dubai and Abu Dhabi, this USD 1.3 billion development blends natural surroundings with exceptional artistry and craftsmanship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512533615/en/ Jacob & Co. Beachfront Living by Ohana. (Photo: AETOSWire) Jacob & Co. Beachfront Living by Ohana presents 457 residences comprising of sea-view apartments, villas, penthouses, Sky Mansions, and beachfront mansions—each capturing the spirit of refined coastal living. Pentho
Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders13.5.2025 07:00:00 CEST | Press release
Financing round led by Jeito Capital and co-led by Forbion Growth, with participation from Seroba, Pictet Group and other existing investorsProceeds to fund two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses as well as expanding the Azafaros pipeline to other indicationsNizubaglustat has been awarded Orphan Drug Designation in both the US and Europe as well as Fast-track status in the US. The company expects to initiate both Phase 3 studies later this year Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announces the completion of an oversubscribed €132M Series B financing led by Jeito Capital, co-led by Forbion Growth and with additional participation from Seroba, Pictet Group and existing investors Forbion Ventures, Schroders Capital and BioGeneration Ventures (BGV). This financing enables Az
Presidio Investors is Pleased to Announce the Addition of Christian Schütte as Its Newest Operating Partner12.5.2025 19:04:00 CEST | Press release
Christian brings more than 20 years of global experience in investment banking, private equity, and operational leadership, with a proven track record of driving transformational growth across industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512473756/en/ Christian Schütte Christian began his career at J.P. Morgan in New York and London, where he worked in the M&A and Corporate Finance teams. He later joined Fortress Investment Group and was instrumental in launching its German operations. During his tenure, he helped raise over €1.5 billion in equity and managed a wide array of investments, including non-performing and performing loans, private and public companies. He went on to join EQT Group, where he focused on mid-market growth and succession investments. Notably, he led the consolidation of nine digital marketing agencies into a €100 million market leader, building one of the most comprehensive digital ma
Introducing Joblio – The Future of Ethical Recruitment12.5.2025 18:30:00 CEST | Press release
Joblio Launches to Revolutionize Ethical Recruitment and End Worker Exploitation Joblio, a global ethical recruitment platform, officially launches today to tackle the broken labor migration system—long plagued by exploitative intermediaries, high recruitment fees, and human rights abuses. With its tech-driven model, Joblio connects vetted workers with employers directly, eliminating unethical middlemen and ensuring cost-free hiring for migrant workers. Employers fund access to talent, but workers never pay—a key step in ending exploitation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512628048/en/ A Mission Rooted in Personal Experience Joblio is led by Jon Purizhansky, a refugee-turned-entrepreneur who experienced migration challenges firsthand. Forced to flee his home country as a young man, Jon faced the uncertainty and vulnerability that millions of migrant workers still encounter today. Now a globally recognized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom